Mawdsleys, working in conjunction with its associate company the DE Group, has completed a joint strategic review of their wholesale activities. The review has concluded that customer interests and the future prospects of both organisations would benefit if they concentrate respectively on the sectors where they have specific market expertise.

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…